Rickettsia rickettsii (Rocky Mountain Spotted Fever) Antibody, IgG
Detects antibodies during convalescent phase.
New York DOH Approval Status
Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.4 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens.
Contaminated, hemolyzed, or severely lipemic specimens.
Mark specimens plainly as "acute" or "convalescent."
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Semi-Quantitative Indirect Fluorescent Antibody (IFA)
|Less than 1:64||Negative - No significant level of IgG antibody detected.|
|1:64 - 1:128||Low Positive - Presence of IgG antibody detected, suggestive of current or past infection.|
|1:256 or greater||Positive - Presence of IgG antibody suggestive of recent or current infection.|
Antibody reactivity to Rickettsia rickettsii antigen should be considered Spotted Fever group reactive. Other organisms within the group include R. akari, R. conorrii, R. australis, and R. sibirica.
Seroconversion, a fourfold or greater rise in antibody titer, between acute and convalescent sera is considered strong evidence of recent infection. Acute-phase specimens are collected during the first week of illness and convalescent-phase samples are generally obtained 2-4 weeks after resolution of illness. Ideally these samples should be tested simultaneously at the same facility. If the sample submitted was collected during the acute-phase of illness, submit a marked convalescent sample within 25 days for paired testing.
|Component Test Code*||Component Chart Name||LOINC|
|0050369||Rocky Mt Spotted Fever IgG||5307-4|
- Rocky Mountain Spotted Fever